Table 4. Randomized phase 2 and 3... | American Society of Hematology

Table 4.

Randomized phase 2 and 3 studies evaluating pomalidomide-based triplets in patients with RRMM

	isa-Pd vs Pd²⁸	PCd vs Pd²⁹	elo-Pd vs Pd³³
Phase	Randomized phase 3	Randomized phase 2	Randomized phase 2
No. of patients	307	70	117
Median of prior lines	3	4	3
Len-refractory, %	93	100	87
Bort-refractory, %	76*	74	80*
Median follow-up, mo	11.6	Not reported	Minimum follow-up of 9.1 mo
≥PR, %	60 vs 35	65 vs 39	53 vs 26
≥VGPR, %	32 vs 9	12 vs 14	20 vs 9
Median PFS, mo	11.5 vs 6.5	9.5 vs 4.4	10.3 vs 4.7 mo
Median OS, mo	1-y OS: 72% vs 63%	Not reached vs 16.8	Not reached in both arms
Approval	FDA/EMA	—	FDA/EMA

	isa-Pd vs Pd²⁸	PCd vs Pd²⁹	elo-Pd vs Pd³³
Phase	Randomized phase 3	Randomized phase 2	Randomized phase 2
No. of patients	307	70	117
Median of prior lines	3	4	3
Len-refractory, %	93	100	87
Bort-refractory, %	76*	74	80*
Median follow-up, mo	11.6	Not reported	Minimum follow-up of 9.1 mo
≥PR, %	60 vs 35	65 vs 39	53 vs 26
≥VGPR, %	32 vs 9	12 vs 14	20 vs 9
Median PFS, mo	11.5 vs 6.5	9.5 vs 4.4	10.3 vs 4.7 mo
Median OS, mo	1-y OS: 72% vs 63%	Not reached vs 16.8	Not reached in both arms
Approval	FDA/EMA	—	FDA/EMA

—, no approval by FDA/EMA; Bort, bortezomib; elo-Pd, elotuzumab-pomalidomide-dexamethasone; isa-Pd, isatuximab-pomalidomide-dexamethasone; Len, lenalidomide; PCd, pomalidomide-cyclophosphamide-dexamethasone; Pd, pomalidomide-dexamethasone.

Refractory to at least 1 PI.

View Large

This Feature Is Available To Subscribers Only